Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes

American Journal of the Medical Sciences

Volumn 351, Issue 4, 2016, Pages 380-386

  Chen, Rong ^a,b   Ovbiagele, Bruce ^b   Feng, Wuwei ^b  

^a HAINAN MEDICAL UNIVERSITY   (China)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Diabetes; Hyperglycemia; Outcomes; Stroke; Stroke prevention

Indexed keywords

ARTICLE; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; HUMAN; HYPERGLYCEMIA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; INSULIN RESISTANCE; PHYSIOLOGY; RISK FACTOR; RISK REDUCTION; STROKE; TREATMENT OUTCOME;

ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT;

CARDIOVASCULAR AGENTS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; RISK FACTORS; RISK REDUCTION BEHAVIOR; STROKE; TREATMENT OUTCOME;

EID: 84987673820     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1016/j.amjms.2016.01.011     Document Type: Article

References (40)

1. 1 Heidenreich, P.A., Trogdon, J.G., Khavjou, O.A., et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123 (2011), 933–944.
2. 2 Putaala, J., Liebkind, R., Gordin, D., et al. Diabetes mellitus and ischemic stroke in the young: clinical features and long-term prognosis. Neurology 76 (2011), 1831–1837.
3. 3 O׳Donnell, MJ, Xavier, D, Liu, L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 376 (2010), 112–123.
4. 4 Collaboration TERF, Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375 (2010), 2215–2222.
5. 5 Wolf, P.A., D׳Agostino, R.B., Belanger, A.J., et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 22 (1991), 312–318.
6. 6 Khoury, J.C., Kleindorfer, D., Alwell, K., et al. Diabetes mellitus: a risk factor for ischemic stroke in a large biracial population. Stroke 44 (2013), 1500–1504.
7. 7 Cui, R., Iso, H., Yamagishi, K., et al. Diabetes mellitus and risk of stroke and its subtypes among Japanese: the Japan public health center study. Stroke 42 (2011), 2611–2614.
8. 8 Iso, H., Imano, H., Kitamura, A., et al. Type 2 diabetes and risk of non-embolic ischaemic stroke in Japanese men and women. Diabetologia 47 (2004), 2137–2144.
9. 9 Manolio, T.A., Kronmal, R.A., Burke, G.L., et al. Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study. Stroke 27 (1996), 1479–1486.
10. 10 Karapanayiotides, T., Piechowski-Jozwiak, B., van Melle, G., et al. Stroke patterns, etiology, and prognosis in patients with diabetes mellitus. Neurology 62 (2004), 1558–1562.
11. 11 Janghorbani, M., Hu, F.B., Willett, W.C., et al. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses׳ Health Study. Diabetes Care 30 (2007), 1730–1735.
12. 12 Lee, M., Saver, J.L., Hong, K.S., et al. Effect of pre-diabetes on future risk of stroke: meta-analysis. Br Med J, 344, 2012, e3564.
13. 13 Tuttolomondo, A., Pinto, A., Salemi, G., et al. Diabetic and non-diabetic subjects with ischemic stroke: differences, subtype distribution and outcome. Nutr Metab Cardiovasc Dis 18 (2008), 152–157.
14. 14 Quast, M.J., Wei, J., Huang, N.C., et al. Perfusion deficit parallels exacerbation of cerebral ischemia/reperfusion injury in hyperglycemic rats. J Cereb Blood Flow Metab 17 (1997), 553–559.
15. 15 Weir, C.J., Murray, G.D., Dyker, A.G., et al. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. Br Med J 314 (1997), 1303–1306.
16. 16 Pandolfi, A., Giaccari, A., Cilli, C., et al. Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat. Acta Diabetol 38 (2001), 71–76.
17. 17 Bruno, A., Levine, S.R., Frankel, M.R., et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 59 (2002), 669–674.
18. 18 Wenjie, C.a.o., Yifeng, Ling, Fei, W.u., et al. Higher fasting glucose next day after intravenous thrombolysis is independently associated with poor outcome in acute ischemic stroke. J Stroke Cerebrovasc Dis 24 (2015), 100–103.
19. 19 Kamalesh, M., Shen, J., Eckert, G.J., Long-term postischemic stroke mortality in diabetes: a veteran cohort analysis. Stroke 39 (2008), 2727–2731.
20. 20 Song, E.C., Chu, K., Jeong, S.W., et al. Hyperglycemia exacerbates brain edema and perihematomal cell death after intracerebral hemorrhage. Stroke 34 (2003), 2215–2220.
21. 21 Jauch, E.C., Saver, J.L., Adams, H.P., et al. Guidelines for the early management of patients with acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44 (2013), 870–947.
22. 22 Olsen, T.S., Langhorne, P., Diener, H.C., et al. European stroke initiative recommendations for stroke management-update 2003. Cerebrovasc Dis 16 (2003), 311–337.
23. 23 Bruno, A., Kent, T.A., Coull, B.M., et al. Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke 39 (2008), 384–389.
24. 24 Johnston, K.C., Hall, C.E., Kissela, B.M., et al. Glucose regulation in acute stroke patients (GRASP) trial: a randomized pilot trial. Stroke 40 (2009), 3804–3809.
25. 25 Bellolio, M.F., Gilmore, R.M., Ganti, L., Insulin for glycaemic control in acute ischaemic stroke. Cochrane Database Syst Rev, 2014, 1 Cd005346.
26. 26 Bruno, A., Durkalski, V.L., Hall, C.E., et al. The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol: a randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke. Int J Stroke 9 (2014), 246–251.
27. 27 Hemphill, J.C. 3rd, Greenberg, S.M., Anderson, C.S., et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 46 (2015), 2032–2060.
28. 28 Lachin, J.M., Orchard, T.J., Nathan, D.M., Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37 (2014), 39–43.
29. 29 Nathan, D.M., Cleary, P.A., Backlund, J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New Engl J Med 353 (2005), 2643–2653.
30. 30 Wing, R.R., Bolin, P., Brancati, F.L., et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New Engl J Med 369 (2013), 145–154.
31. 31 Gaede, P., Lund-Andersen, H., Parving, H.H., et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. New Engl J Med 358 (2008), 580–591.
32. 32 Program NHBPE. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda (MD): National Heart, Lung, and Blood Institute (US), 2004.
33. 33 James, P.A., Oparil, S., Carter, B.L., et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). J Am Med Assoc 311 (2014), 507–520.
34. 34 Group UPDS, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 UK Prospective Diabetes Study Group. Br Med J 317 (1998), 703–713.
35. 35 Cushman, W.C., Evans, G.W., Byington, R.P., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. New Engl J Med 362 (2010), 1575–1585.
36. 36 Kernan, W.N., Ovbiagele, B., Black, H.R., et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45 (2014), 2160–2236.
37. 37 Committee CS, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996), 1329–1339.
38. 38 Kunte, H., Busch, M.A., Trostdorf, K., et al. Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas. Ann Neurol 72 (2012), 799–806.
39. 39 Dormandy, J.A., Charbonnel, B., Eckland, D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
40. 40 Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. The New England Journal of Medicine [epub ahead of print] 2016.